Haisco Pharmaceutical Group Co. Ltd. has reported fibroblast growth factor receptor 2 (FGFR2) and FGFR3 inhibitors potentially useful for the treatment of cancer.
A Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. patent describes the discovery of new proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety covalently linked to a GTPase KRAS-targeting moiety. They are reported to be useful for the treatment of cancer.
Chengdu Kendite Biomedical Technology Co. Ltd. has synthesized pyrimidopyrazole compounds acting as non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors. They are reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease, dermatological and inflammatory disorders.
Neuroblastoma cells harbor a pattern of chromosomal aberrations that include chromosomes 1p and 11q deletions and 2p and 17q gains, as well as MYCN gene amplification with MYC overexpression. Recent research has identified RuvB-like 1 (RUVBL1) and RUVBL2 to be key mediators of the therapeutic response to a promising strategy such as serine/threonine-protein kinase ATR inhibition.
Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have patented 20-hydroxyeicosatetraenoic acid (20-HETE) production inhibitors. They are reported to be useful for the treatment of cancer, obesity, diabetes, Alzheimer’s and Parkinson’s disease, osteoporosis, cardiovascular and cerebrovascular disorders, among others.
Bromodomain-containing protein 4 (BRD4) is an epigenetic regulator that promotes transcription of oncogenic drivers such as MYC and contributes to tumor growth and therapy resistance in colorectal cancer, making it a promising therapeutic target. Researchers from Hangzhou Kexing Biochem Co. Ltd. described the discovery and preclinical characterization of compound [I], a potent BRD4 inhibitor.
IRAK1, a key mediator of TLR/IL-1R signaling, drives tumor cell proliferation and a pro-inflammatory microenvironment when aberrantly activated. Its overexpression has been observed in multiple cancers, including hepatocellular carcinoma (HCC).
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported. Because cancer cells and HIV-infected cells have similar features, researchers from City of Hope National Medical Center tested the anit-HIV effects of a small-molecule compound, AOH-1996, that targets caPCNA.
RSS
